73results about How to "Optimize treatment plan" patented technology

Real-time and individualized disease monitoring is central to rapidly evolving medical sciences and technologies, but for the vast majority of patients, disease progression and treatment are monitored only in an irregular and discontinuous fashion. Consequently, disease progression and relapse are often allowed to proceed too far before they are detected, compromising the possibility of any effective treatment. For one patient, this can mean becoming refractory to the few early drug treatments that are available; for another, missing early detection may be deadly. This invention provides a method for the detection of early signals of disease and recovery thereof comprising a universal yet personalized health-monitoring solution using cell phones or other wearable smart device data that generate extensive real-time data. The invention further provides a system and method to provide answers to a variety of questions related to the patient health status and health trajectory. Its flexibility and generality is designed for a preferred application to rare disorders and rare questions for which other analytical system are lacking.

The invention provides methods of treating or preventing a condition or disorder associated with dyslipidemia with compositions comprising apolipoprotein-sphingomyelin complexes. The methods of the invention permit reduction, by 4- to 20-fold, of the amount of apolipoprotein required for therapeutic administration to bring about an ameliorative effect.

A non-invasive apparatus for rehabilitating a joint, limb, and muscles of a patient recovering from surgery on the joint, includes a continuous passive motion device having at least one support member for supporting the limb, at least one hinge coupled to the at least one support member, and at least one actuator for providing reciprocating motion of the at least one support member about the at least one hinge, a plurality of electrodes transmitting at least four modalities chosen from a group consisting of functional electrical stimulation (FES), transcutaneous electrical nerve stimulation (TENS), temperature therapy stimulation, deep vein thrombosis (DVT) prophylactic stimulation, venous blood flow monitoring, and pain monitoring, and a control unit controlling the at least one actuator and the plurality of electrodes according to a coordinated sequence of the reciprocating motion and transmission of the at least four modalities.

The present invention relates to a radiation treatment planning system and a corresponding computer program product. The system comprises means for graphically displaying an image representing a target area 10 to be treated with a set o therapeutic radiation beams and an adjacent structure comprising healthy tissue 14 and / or organs at risk 12, and for displaying corresponding dose values according to a preliminary treatment plan. The system further comprises means for allowing a user to interactively input a local dose variation, local dose variation means for revising the preliminary treatment plan such as to account for the local dose variation inputted by the user and dose recovery means comprising means for revising the treatment plan again such as to at least partially compensate for a change of dose in a predetermined recovery area caused by said dose variation.

The invention discloses a realizing method for a long-distance electrocardiogram monitoring system with automatic analyzing and real-time information sharing functions. The method comprises the steps that 1, automatic dynamic electrocardiogram analyzing equipment collects electrocardiogram signals and motion sensor signals and analyzes the signals in real time; 2, the automatic dynamic electrocardiogram analyzing equipment transmits analysis results in a wireless mode through a low-power-consumption Bluetooth communication module; 3, a user monitoring terminal receives data, processes the data locally in real time and the transmits the data to a long-distance monitoring terminal; 4, information received by the long-distance monitoring terminal is transmitted to a long-distance index real-time analysis processing and early warning module, and processed results are submitted to an information sharing module; 5, the information sharing module enables received information to be shared in real time according to the preset share range and the sharing mechanism. The method has the advantages that data wirelessly transmitted are reduced to the maximum degree, human intervention is reduced, high automation degree analysis is achieved, and the real-time prediction and early warning ability of severe events is improved.

A radiotherapy system comprising at least one pulsed radiation source, at least one imaging system, a control system, and a synchronization system is disclosed. The pulsed radiation source deposits high dose radiation pulses to a target region inside the patient; simultaneously the imaging system is used to monitor the target region, synchronized by the synchronization system. The dose per radiation pulse is high enough to deposit, within few pulses, 1 Gy at a depth of at least 1 cm in water. At each irradiation time step, the pulsed radiation source delivers short pulses of radiation (<1 ms) and the imaging system performs a snapshot of the position, and eventually the shape, of the target region during the irradiation time, with a time resolution better than 200 ms. Being both the pulsed radiation source and imaging system synchronized by the synchronization system with less than 200 ms jitter, this system allows for very precise reconstruction of the map of the dose deposited into the target region.

The present disclosure provides a brachytherapy apparatus that delivers a low dose, partial breast irradiation treatment for post-lumpectomy patients via introduction of a catheter-like device through a cannula. The apparatus may be introduced post-surgically with local anesthesia under image guidance into the previous excision site and into a cavity by a surgeon. The brachytherapy apparatus includes a seed containment device configured to contain a plurality of low-dose radioactive seeds therein. The seed containment device may be one or more thin-walled tubes. The apparatus is further configured to expand so that at least a portion of the seed containment device is positioned against the remaining tissue and the plurality of radioactive seeds are disposed at the perimeter of the seed containment device. Also described are various clamps for the apparatus, and sleeves for adjusting the size of the device to fit a cavity when the apparatus is in use.

Disclosed herein is a device, and method for treating heart failure by electrically modulating a splanchnic nerve with an implantable device.

The invention provides an intelligent assisted diagnosis method for children respiratory diseases and a diagnosis system thereof. The method comprises the steps of S1, acquiring assisted examination information of a to-be-diagnosed child and / or doctor interrogation diagnosis recording information; S2, according to the assisted examination information and / or doctor interrogation diagnosis recordinginformation, screening key information; and S3, according to a pre-established children disease knowledge database system, processing the key information by means of a pre-trained typical symptom diagnosis model, thereby obtaining a diagnosis result. The diagnosis result comprises at least one possible disease, and the characteristic, which corresponds with each possible disease, of the to-be-diagnosed child. The intelligent assisted diagnosis method can help non-expert doctors in improving diagnosis levels for difficult disease, thereby reducing misdiagnosis.

Disclosed herein is a device, and method for treating heart failure by electrically modulating a splanchnic nerve with an implantable device.

The present invention relates to the detection of antibiotic resistance determinants in Staphylococcus aureus. The present invention discloses a micro-array for the detection of antibiotic resistance determinants and mutations in said organism, a method for the detection of said determinants and mutations and a kit.

The invention provides a Pseudomonas exotoxin A (PE) comprising an amino acid sequence having a substitution of one or more B-cell and / or T-cell epitopes. The invention further provides related chimeric molecules, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions. Methods of treating or preventing cancer in a mammal, methods of inhibiting the growth of a target cell, methods of producing the PE, and methods of producing the chimeric molecule are further provided by the invention.

The present invention relates to an attenuated mutant strain of Salmonella comprising a recombinant DNA molecule encoding Mesothelin. In particular, the present invention relates to the use of said attenuated mutant strain of Salmonella in cancer immunotherapy.

The invention discloses a breast cancer patient disease-free lifetime prediction model and a construction method thereof. The method builds a breast cancer patient disease-free lifetime artificial intelligence prediction model by employing an artificial intelligence machine learning algorithm based on the magnetic resonance image data and clinical feature data of a breast cancer patient, and can make early breast cancer patients effectively divided into a high-risk group and a low-risk group. The prediction model has the advantages of accuracy, simplicity, convenience, noninvasiveness and thelike, can effectively evaluate the postoperative disease-free lifetime of early breast cancer patients, is helpful for assisting clinicians to optimize treatment schemes, strengthens treatment intervention on high-risk patients as soon as possible, reduces recurrence risks of the patients, and has important guiding significance for guiding clinical treatment strategies and enhancing clinical treatment intervention and subsequent individualized follow-up visits.

The invention relates to an intelligent wearable monitoring system based on a flexible fabric sensor and a monitoring method; the intelligent wearable monitoring system comprises the flexible fabric sensor, a simulation glove, a data acquisition circuit, a controller and a PC (personal computer); the flexible fabric sensor is a resistive flexible knit strain sensor and is bonded to each finger in the simulation glove through high-elasticity hot-melt film, a data acquisition control device composed of the data acquisition circuit and the controller is packaged in a releasable insulating box and is fixed at the outer side of the simulation glove, a lead of the flexible fabric sensor is connected to the acquisition input end of the data acquisition control device fixed at the outer side of the simulation glove, the output end of the data acquisition control device is connected to the input end of a storage through a USB (universal serial bus) cord, the output end of the storage is connected to the PC, and the PC is one in which a rehabilitation training estimation system is installed. The intelligent wearable monitoring system and the monitoring method can provide more accurate real-time monitoring and can also provide remote monitoring, such that time is saved for patients and physicians.

The invention discloses an effect study method of melatonin in prediction of ovarian reserve and IVF-ET (in-vitro fertilization and embryo transfer) outcome. The method includes: collecting basic clinical data of 61 females, and dividing the 61 females into three groups, namely a poor ovarian response group, a normal ovarian response group and a high ovarian response group mainly through age, retrieved oocyte number and anti-mullerian hormone value according to the stimulus response of the ovaries; collecting follicular fluid of the 61 females, adopting melatonin radioimmunoassay to determine melatonin concentration in the follicular fluid of the 61 females, and analyzing the levels of the melatonin concentration and other clinical data in the poor ovarian response group, the normal ovarian response group and the high ovarian response group; analyzing the levels of relevant data of in-vitro fertilization outcome in the poor ovarian response group, the normal ovarian response group and the high ovarian response group, and verifying relevance of the melatonin concentration and IVF-ET outcome; verifying relevance of the melatonin level and ovarian reserve. Through detection of melatonin concentration in the follicular fluid, ovarian reserve and IVF-ET outcome are predicted.

The invention discloses a management system and a method for respiratory drug administration information. The system comprises a respiratory drug administration device and an individual data management terminal, wherein the respiratory drug administration device comprises a drug container, a drug release switch, a drug administration channel, a drug administration information acquisition module and a wireless communication module; the drug administration information acquisition module is electrically connected with the wireless communication module; the system also comprises a cloud big data management platform and a medical monitoring platform. By means of the system and the method, high-quality big data can be established to serve as medical research support, the quantization reference standard is provided for patients and medical workers, and research on disease treatment is promoted; medical workers can master the medication condition and the treatment effect of the patients to improve treatment schemes; the patients can conveniently and scientifically adjust the drug administration scheme and can know the recovery effect of diseases.

Stabilized liquid pharmaceutical composition comprising an interferon (IFN) or an isoform, mutein, fused protein, functional derivative, active fraction or salt thereof, wherein said formulation is a solution that comprises a buffer, a cyclodextrin, an isotonicity agent and an anti-oxidant are described here. Preferably the interferon is interferon beta-1a and the cyclodextrin is HPBCD. These formulations are stable at room temperature, thus bringing the advantage of lower costs for formulation storage and increased safety for the patient with respect to possible “errors” during handling. As a matter of fact, having such formulations stable at room temperature reduces the risk of formation of degradation products potentially responsible for adverse events (e.g. immunogenicity).

The invention discloses a Kelarmycin dry suspensoid and its preparing process consisting of, subjecting the Kelarmycin to twice granulation, i.e. mixing with a quantitative of binding agent, granulation and drying, coating a film dressing layer to the obtained particles with macromolecular dressing material, mixing auxiliary materials including suspension aid, bulking agent, flavoring agent, acid and alkali conditioning agent, forming pellets, and mixing with dressing particles.

The present disclosure provides a brachytherapy apparatus, system and method that delivers partial breast irradiation treatment for post-lumpectomy patients via introduction of a catheter-like device through a trocar. The apparatus may be introduced post-surgically with local anesthesia under image guidance into the previous excision site and into a cavity by a surgeon. The brachytherapy apparatus includes one or more thin-walled tubes, each of said thin-walled tubes being configured to contain one or more radioactive sources, at least one radiation source configured to deliver a prescribed dose of radiation, a whisk adjuster configured to permit adjustment of each of the one or more thin-walled tubes so that the tubes substantially conform to a size of the body cavity; and an expansion element configured to expand outwardly said one or more thin-walled tubes within the cavity so that the thin-walled tubes substantially conform to a shape and / or size of the body cavity.

Described herein are nanoparticle conjugates that demonstrate enhanced penetration of tumor tissue (e.g., brain tumor tissue) and diffusion within the tumor interstitium, e.g., for treatment of cancer. Further described are methods of targeting tumor-associated macrophages, microglia, and / or other cells in a tumor microenvironment using such nanoparticle conjugates. Moreover, diagnostic, therapeutic, and theranostic (diagnostic and therapeutic) platforms featuring such nanoparticle conjugates are described for treating targets in both the tumor and surrounding microenvironment, thereby enhancing efficacy of cancer treatment. Use of the nanoparticle conjugates described herein with other conventional therapies, including chemotherapy, radiotherapy, immunotherapy, and the like, is also envisaged.

A method for planning an infusion into hepatic tissue into a patient includes: obtaining anatomical and / or physiological patient data of the patient's liver or a region of the liver; determining at least one patient parameter from the patient data; planning the infusion using the anatomical patient data, physiological patient data, and / or at least one patient parameter, wherein planning includes determining how an administered substance is distributed in the tissue and / or how the administered substance influences physiological properties of the tissue; and determining a distribution and / or effectiveness of a therapeutic agent administered with the substance or after the substance.

A slowly-releasing composite medicine for treating the diseases in respiratory system is prepared from Fuduositan (15-30 Wt %), clarithromycin (10-40), and auxiliary (rest) including paralyser.

Tetrahydroberberine (THB), isolated from the Chinese herb “Corydalis ambigua”, exhibits a variety of pharmacological effects, although mechanisms of action are unclear or entirely unknown. Described herein are novel methods of using tetrahydroberberine (THB), THB analogs or derivatives, tetrahydroprotoberberines (THPB). Tetrahydroberberine (THB) and analogs such as l-stepholidine (l-SPD) potently block functional KATP channels natively expressed on midbrain dopamine neurons. Further, THB also blocks pancreatic β-cell KATP channels, and can be developed to a novel drugs for treating disease and / or conditions such as diabetes and Parkinson's disease.

The invention relates to a tumor marker and an application thereof, in particular to an application of at least one of a C10orf71 gene, a C10orf71 protein and a C10orf71 gene detection primer kit in preparation of a product for predicting response of a cancer patient to neoadjuvant chemotherapy. According to the invention, the C10orf71 gene mutation is determined to be a key molecular characteristic of tumor response to neoadjuvant chemotherapy for the first time, and based on the technical scheme of the invention, the neoadjuvant chemotherapy has advantages in improvement of prognosis and determination of responsive patients before treatment, so that a better treatment scheme can be formulated.

A non-invasive apparatus for rehabilitating a joint, limb, and muscles of a patient recovering from surgery on the joint, includes a continuous passive motion device having at least one support member for supporting the limb, at least one hinge coupled to the at least one support member, and at least one actuator for providing reciprocating motion of the at least one support member about the at least one hinge, a plurality of electrodes transmitting at least four modalities chosen from a group consisting of functional electrical stimulation (FES), transcutaneous electrical nerve stimulation (TENS), temperature therapy stimulation, deep vein thrombosis (DVT) prophylactic stimulation, venous blood flow monitoring, and pain monitoring, and a control unit controlling the at least one actuator and the plurality of electrodes according to a coordinated sequence of the reciprocating motion and transmission of the at least four modalities.

Stabilized liquid pharmaceutical composition comprising an interferon (IFN) or an isoform, mutein, fused protein, functional derivative, active fraction or salt thereof, wherein said formulation is a solution that comprises a buffer, a cyclodextrin, an isotonicity agent and an anti-oxidant are described here. Preferably the interferon is interferon beta-1a and the cyclodextrin is HPBCD. These formulations are stable at room temperature, thus bringing the advantage of lower costs for formulation storage and increased safety for the patient with respect to possible “errors” during handling. As a matter of fact, having such formulations stable at room temperature reduces the risk of formation of degradation products potentially responsible for adverse events (e.g. immunogenicity).

The invention discloses a preparing adjusting method of a CRRT local citric acid anticoagulation substitution fluid. The method comprises the steps of inputting a CRRT treating parameter and a biochemical and blood gas test result; adjusting the speed of citric acid in front of a pump, and controlling the target concentration of plasma citric acid at 3.5-4.0 mmol / L; according to the concentration of formula ionized calcium, and with the combination of the concentration of blood gas ionized calcium in front of a filter and the predicted input speed of 5% calcium chloride, adjusting a peripheral calcium supplement parameter; according to the concentration of blood gas bicarbonate, and with the combination of the concentration of blood gas bicarbonate in front of a filter, adjusting a peripheral sodium bicarbonate supplement parameter; according to the concentration of sodion, and with the combination of the concentration of blood gas sodion in front of a filter, adjusting a formula basic liquid injection water using amount. Therefore, not only can the speeds of sodium citrate and calcium supplement be accurately predicted in a personalized mode according to the CRRT treating parameter and the patient condition, but also the degree of influences of the substitution fluid on all electrolytes in blood and acid-base in the treating process can be predicated, and synchronous adjustment on a CRRT local citric acid anticoagulation substitution fluid formula is achieved.